Batea Oncology, a Spanish biotechnology company dedicated to developing innovative therapies for solid tumors, leads the GlioProof project, which aims to improve the treatment of glioblastoma (GB), one of the most aggressive brain tumors with the poorest prognosis.
The project focuses on GlioHook, an implantable medical device designed to be placed in the surgical cavity after tumor resection. This biomaterial captures residual cancer cells and increases their sensitivity to radiotherapy, acting during the critical period between surgery and the start of conventional treatment. Its mechanism of action combines tumor targeting with radiosensitization, offering a complementary, non-pharmacological approach that integrates seamlessly into current clinical practice.
Thanks to the support of the 2024 Public-Private Collaboration programme, GlioProof will enable the completion of preclinical regulatory studies and the execution of a multicentre pilot clinical trial involving the Vall d’Hebron Institute of Oncology (VHIO), HM Hospitales Foundation and the Santiago Health Research Institute Foundation (FIDIS). Preclinical studies already show significant improvements in survival and a reduction in tumor invasion.
If confirmed in humans, GlioHook could benefit more than 120,000 patients per year worldwide, improving survival and quality of life while reducing costs associated with relapses and additional treatments. With GlioProof, Batea Oncology strengthens the transfer of biomedical technology from research to clinical practice, consolidating its position as a benchmark in translational oncology innovation.
